Needham Maintains Buy on Harmony Biosciences, Lowers Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) but has lowered the price target from $66 to $53.
October 16, 2023 | 10:04 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst has maintained a 'Buy' rating on Harmony Biosciences but lowered the price target from $66 to $53.
The news is directly related to Harmony Biosciences. While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100